
Sipavibart EMA Regulatory Submission Approved for Accelerated Assessment in COVID-19 Prevention
AstraZeneca’s Marketing Authorisation Application (MAA) for sipavibart has been accepted under the accelerated assessment procedure by the European Medicines Agency (EMA) for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients. Sipavibart is an investigational long-acting antibody designed to provide…











